Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | STAT3 | P40763 | 17/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loganic Acid SCHEMBL31179995 | 1.00 | MAPT (1.00) | MAPTSTAT3MEN1KMT2A | |
| Loganic Acid SCHEMBL308008 | 1.00 | MAPT (1.00) | MAPTSTAT3MEN1KMT2A | |
| SCHEMBL29426057 | 0.90 | STAT3 (0.85) | MAPTSTAT3MEN1KMT2A | |
| Loganin SCHEMBL21114425 | 0.90 | STAT3 (1.00) | MAPTSTAT3MEN1KMT2A | |
| Loganin SCHEMBL29425815 | 0.90 | STAT3 (1.00) | MAPTSTAT3MEN1KMT2A | |
| Loganin SCHEMBL23805433 | 0.90 | STAT3 (1.00) | MAPTSTAT3MEN1KMT2A | |
| Loganin SCHEMBL307017 | 0.90 | STAT3 (1.00) | MAPTSTAT3MEN1KMT2A | |
| Loganin SCHEMBL23805434 | 0.90 | STAT3 (1.00) | MAPTSTAT3MEN1KMT2A | |
| Loganin SCHEMBL29402517 | 0.90 | STAT3 (1.00) | MAPTSTAT3MEN1KMT2A | |
| SCHEMBL29426175 | 0.88 | MAPT (0.79) | MAPTSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702037-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20260007710-A1 | PRODUCTION PROCESS FOR CONTROLLING THE ACTIVE INGREDIENTS OF Cistanche deserticola Ma | SICHUAN JUYUAN CHINESE MEDICINE HERBAL PIECES CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| CN-119529001-A | Efficient cistanche extraction method | 陕西青溪生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024224085-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| EP-3409766-B1 | AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS | N ZYME BIOTEC GMBH (DE) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007710-A1 | PRODUCTION PROCESS FOR CONTROLLING THE ACTIVE INGREDIENTS OF Cistanche deserticola Ma | SAMM50, NSF, VAMP7 | MAPT 2519/4885STAT3 2828/4885MEN1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.